Thromboembolism and Anticoagulation in Pancreatic Cancer
Pancreatic cancer is a hypercoagulable condition, and venous thromboembolism affects up to 17% to 57% of pancreatic cancer patients. Initiating chemotherapy further increases the risk. For cancer patients initiating chemotherapy, there is currently no approved treatment for the primary prevention of venous thromboembolism risk. The authors summarize the two abstracts (#151 and #284) presented at the 2013 ASCO Gastrointestinal Cancers Symposium which were focused newer treatment options and the incidence of thromboembolism in pancreatic cancer patients especially in East Asian patients. Additionally the authors review the risk of thrombosis associated with the chemotherapy and erythropoiesis stimulating agents and its prognostic implications and possible managements.
Image: St. Elizabeth’s Medical Center. Brighton, MA, USA.
Shaib, W., et al., Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients. Anticancer Res, 2010. 30(10): p. 4261-4.
Sgouros, J. and A. Maraveyas, Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of phase III chemotherapy studies in advanced pancreatic cancer. Acta Oncol, 2008. 47(3): p. 337-46.
Chew, H.K., et al., Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med, 2006. 166(4): p. 458-64.
Al Diab, A.I., Cancer-related venous thromboembolism: insight into underestimated risk factors. Hematol Oncol Stem Cell Ther, 2010. 3(4): p. 191-5.
Burtness, B., et al., Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancer. Cancer J, 2007. 13(4): p. 257-62.
Riess, H., et al., Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer, 2008. 8: p. 361.
Sigal, D.M., GM. Rosen, SJ. Lee, P. Nguyen, T. Gribbin, TE. Diez, PQ. Borad, MJ. , Association of 2-O, 3-O desulfated heparin (ODSH) plus combination gemcitabine (G)/ nab-paclitaxel (A) with preliminary benefit in untreated metastatic pancreatic cancer. J Clin Oncol, 2013. 30(Suppl 34; Abst 284)).
Lee, J.C., J. Ro, YS. Hyejin, C. , Venous thromboemboembolism in patients with pancreatic cancer: Incidence and effect on survival in east Asian ethnic groups. J Clin Oncol, 2013. 30(Suppl 34; Abstr 151)).
Burris, H.A., 3rd, et al., Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol, 1997. 15(6): p. 2403-13.
Becouarn, Y., et al., A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Federation Nationale des Centres de Lutte Contre le Cancer. Ann Oncol, 2007. 18(12): p. 2000-5.
Oh, S.Y., et al., Venous thromboembolism in patients with pancreatic adenocarcinoma: lower incidence in Asian ethnicity. Thromb Res, 2008. 122(4): p. 485-90.
Nakchbandi, W., et al., Prospective study on warfarin and regional chemotherapy in patients with pancreatic carcinoma. J Gastrointestin Liver Dis, 2008. 17(3): p. 285-90.
Icli, F., et al., Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J Surg Oncol, 2007. 95(6): p. 507-12.
Copyright (c) 2014 Muzzamal Habib, Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.